ERS manages an extensive global network that connects you with leading academic experts, high-volume prescribers, and payer and policy influencers, among other stakeholders.
We have six dedicated ERS team members who work closely with our consulting staff to customize and manage recruitment for all market research engagements. ClearView conducted more than 8,000 interviews in 2018 alone, with experts in our network located in over 40 geographies including all major established and emerging markets. Our world-class network of over 5,000 experts spans more than 45 therapeutic areas. We are constantly expanding our network reach and can perform custom recruitment for nearly any stakeholder to address your key questions.
ERS provides guidance and support across an extensive range of market research needs, from traditional telephone interviews, to surveys, in-person interviews, multi-stakeholder interviews, and live or web-based focus groups.
Clinical and scientific key opinion leaders
High-volume prescribers
Active and recent U.S. payers
Recent EU payer and payer experts
Cross-functional industry experts
Other healthcare professions (first responders, case managers)
Patient advocacy groups
Patients and caregivers
Web-assisted tele-depth interviews
In-person interviews
Quantitative surveys
Patient chart reviews
Patient chart reviews
Patient journals / diary entries
Advisory boards
Live and virtual focus groups
Dyads and triads
ClearView maintains strict compliance procedures to ensure that all research adheres to industry best practices, recording laws, market research regulations and product safety reporting as well storage and destruction protocol. The ERS team trains each member of the consulting staff on all compliance standards and helps facilitate onboarding to your company’s specific compliance training and requirements where needed. ClearView is a member of the BHBIA and is compliant with all current interpretations of the GDPR.
For more information on data privacy, view the ClearView Healthcare Partner Privacy Notice.